Redeye endorses Inhalation Sciences’ order worth approximately SEK3.2m from a large, returning European pharma company. We argue the order validates ISAB’s offering, and we look forward to the company’s Q3 report next week. Moreover, we reiterate our base case of SEK17.

Link to the analysis